BEST
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
- Stage
- klaar
- Medicine
- bexagliflozin
- Population
- Diabetes Mellitus
- Phase
- III
- First Patient In
- 26 September 2016
- Last Patient In
- 8 March 2018
- Last Patient Last Visit
- 30 April 2019
National Lead
